Press Releases

Mithra Announces Completion of Recruitment in Donesta® Phase II Study
13 October 2017
EN FR

Mithra’s Marketing Authorization Application for Tibelia® Accepted by Health Canada
10 October 2017
EN FR

Mithra Signs Commercial Agreement With Brazilian Leader in Women’s Health Libbs for Estelle® in Brazil
26 September 2017
EN FR

Mithra announces 2017 half year results
21 September 2017
EN FR

Half year 2017 Results
21 September 2017
EN FR

Mithra Announces First Subject Completes Estelle® Phase III Study
18 August 2017
EN FR

Recruitment Completed in Estelle® Population PK Substudy
9 August 2017
EN FR

Mithra Submits Myring™ for European Marketing Approval
17 July 2017
EN FR

Mithra Strengthens E4 Patent Position in Australian Market
6 July 2017
EN FR

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean
28 June 2017
EN FR

Information on the total number of voting rights (denominator)
27 June 2017
EN FR

Estelle® Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal
26 June 2017
EN FR

Mithra Successfully Raises €26.1 Million
21 June 2017
EN FR

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering
21 June 2017
EN FR

Mithra Completes Recruitment for Additional Estelle® Safety Study
21 June 2017
EN FR

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy
9 June 2017
EN FR

Mithra Signs Exclusive Agreement for Tibelia® in Canada
6 June 2017
EN FR

Mithra Obtains Marketing Authorization for Tibelia® in France
29 May 2017
EN FR

Mithra Receives GMP Approval for Myring™ Production
23 May 2017
EN FR

Mithra and Gynial Sign Commercialization Agreement For Myring™ in Austria
19 May 2017
EN FR

Mithra to Initiate PK Study for Estelle®
12 May 2017
EN FR

Mithra Pharmaceuticals releases 2016 Annual Report and invitation to its Ordinary General Shareholders’ Meeting
18 April 2017
EN FR

Annual Report 2016
18 April 2017
EN FR

Mithra Reports 2016 Annual Results
2 March 2017
EN FR

Mithra Signs a Binding Term Sheet with the Japanese Leader in Women’s Health Fuji Pharma to Commercialize Donesta® in Japan and ASEAN
1 March 2017
EN FR

Mithra Agrees Exclusive Long-Term License and Supply Agreement with Mayne Pharma to Commercialize Myring in the US
28 February 2017
EN FR

Mithra Granted EUR 1.9 million in Non-Dilutive Funding
13 February 2017
EN FR

Mithra Completes Recruitment for European Phase III Estelle® Study
7 February 2017
EN FR

Mithra Strengthens Position in the Belgian Contraception Market
31 January 2017
EN FR

Mithra Plans to Submit Myring for US and EU Approval in Q2 2017
24 January 2017
EN FR

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive
18 January 2017
EN FR

Mithra’s North American Advisory Board for Donesta® Will Meet in Miami, Florida the 20th- 21st January 2017
12 January 2017
EN FR

Mithra Announces 2017 Financial Calendar
11 January 2017
EN FR

Publication of a Transparency Notification Received by Mithra Pharmaceuticals SA/NV
9 January 2017
EN FR NL

Transparency Notification – Bart Versluys
9 January 2017
NL

Appointment of Christophe Maréchal as Chief Financial Officer
6 January 2017
EN FR